RNA-Modulating Agents Tissue-Specific Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery strategies for siRNAs and miRNAs fail to effectively and selectively silence disease-causing or viral genes in specific tissues, lacking systemic administration with tissue-specific action.
Innovation Solution
Development of RNA-modulating agents comprising multiple miRNA binding sequences that recruit small regulatory RNA molecules to target mRNAs, allowing for tissue-specific or cell-type specific gene modulation by enhancing binding affinity and potency through specific Watson-Crick base pair combinations and mismatches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current delivery strategies for siRNAs and miRNAs are used, then gene silencing can be achieved, but tissue-specific selectivity and effective systemic delivery are not achieved
Solution Approach 1:
The patent employs tissue-specific miRNAs as intermediaries to achieve selective gene silencing. The RNA-modulating agent contains multiple miRNA binding sequences that recruit endogenous tissue-specific miRNAs (such as miR-122 in liver, miR-1 in muscle) to mediate target mRNA degradation only in specific tissues where these miRNAs are naturally expressed, thereby achieving both reliable gene silencing and tissue-specific selectivity through systemic administration
Solution Approach 2:
The patent creates composite RNA-modulating agents that combine multiple functional elements: (1) target mRNA binding sequences, (2) multiple miRNA binding sequences with specific Watson-Crick base pair combinations and mismatches, and (3) Argonaute protein recruitment motifs. This composite structure enables simultaneous achievement of stable mRNA binding, enhanced miRNA recruitment potency, and tissue-specific delivery through systemic administration
2Reliability
If RNA-modulating agents with single miRNA binding sequence are used, then some gene modulation is achieved, but potency is insufficient
Solution Approach 1:
The patent merges multiple miRNA binding sequences into a single RNA-modulating agent molecule. The agent contains at least two miRNA binding sequences that can simultaneously or sequentially recruit multiple miRNA molecules to the target mRNA, creating a synergistic effect that dramatically enhances potency (over 10-fold improvement) compared to agents with single miRNA binding sequences
Solution Approach 2:
The patent optimizes the parameters of miRNA binding sequences by designing specific combinations of Watson-Crick base pairs and mismatches at defined positions. The binding sequences are engineered to be complementary to specific positions of the miRNA (e.g., positions 2-8 and 12-25, but not positions 10-11), creating optimal binding affinity and specificity that enhances recruitment potency while maintaining selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA-modulating agents achieve potent inhibition of target mRNA translation or destabilization, enabling tissue-specific or cell-type specific gene silencing, including viral genes, with improved potency over single miRNA binding sequence agents.
Implementation Method 1
the potency of an RNA-modulating agent comprising two or more miRNA binding sequences can be further improved (e.g., over 10-fold) by employing miRNA binding sequences that have specific combinations of Watson-Crick base pairs and mismatches with their cognate miRNA binding partner
Data Source
AI summary
The instant disclosure provides RNA-modulating agents that function to recruit one or more small regulatory RNA molecules (e.g., miRNA molecules, Y RNAs, and siRNAs) to a target mRNA thereby modulating (e.g., inhibiting) the translation of the target mRNA or destabilizing the mRNA. Also provided are miRNA inhibitors and diagnostic agents that have improved binding affinity for their target miRNAs. Methods for using the RNA-modulating agents, miRNA inhibitors and diagnostic agents are also provided.